Illumina, Inc. (NASDAQ:ILMN) – Equities researchers at William Blair cut their FY2018 earnings per share estimates for Illumina in a research note issued to investors on Tuesday. William Blair analyst A. Murphy now anticipates that the life sciences company will post earnings per share of $4.36 for the year, down from their previous estimate of $4.37.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.14. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The business had revenue of $662 million during the quarter, compared to analyst estimates of $642.38 million. During the same period in the prior year, the company posted $0.86 EPS. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year.
Several other analysts have also weighed in on ILMN. Vetr raised shares of Illumina from a “buy” rating to a “strong-buy” rating and set a $196.75 price objective for the company in a report on Monday, April 24th. Cantor Fitzgerald raised their price objective on shares of Illumina from $155.00 to $170.00 and gave the stock a “neutral” rating in a report on Wednesday, April 26th. Cowen and Company reaffirmed an “outperform” rating and set a $200.00 price objective on shares of Illumina in a report on Wednesday, April 26th. Deutsche Bank AG reaffirmed a “hold” rating and set a $175.00 price objective (up previously from $165.00) on shares of Illumina in a report on Saturday, April 29th. Finally, Morgan Stanley reaffirmed an “underweight” rating and set a $115.00 price objective (up previously from $108.00) on shares of Illumina in a report on Monday, May 15th. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $177.01.
Shares of Illumina (ILMN) traded down 0.25% during trading on Wednesday, reaching $190.73. The company had a trading volume of 453,256 shares. The firm has a 50-day moving average of $181.07 and a 200-day moving average of $174.67. Illumina has a 12-month low of $119.37 and a 12-month high of $199.95. The company has a market cap of $27.85 billion, a P/E ratio of 38.27 and a beta of 0.83.
In other news, Director Frances Arnold sold 825 shares of Illumina stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $174.77, for a total transaction of $144,185.25. Following the transaction, the director now directly owns 8,816 shares of the company’s stock, valued at $1,540,772.32. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Jay T. Flatley sold 20,000 shares of Illumina stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $194.73, for a total transaction of $3,894,600.00. Following the transaction, the director now directly owns 539,176 shares in the company, valued at $104,993,742.48. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 154,010 shares of company stock worth $27,840,615. Insiders own 1.60% of the company’s stock.
Several institutional investors have recently made changes to their positions in the company. Nisa Investment Advisors LLC boosted its position in shares of Illumina by 41.0% in the first quarter. Nisa Investment Advisors LLC now owns 6,190 shares of the life sciences company’s stock worth $1,056,000 after buying an additional 1,800 shares in the last quarter. State of Tennessee Treasury Department boosted its position in shares of Illumina by 7.8% in the first quarter. State of Tennessee Treasury Department now owns 97,850 shares of the life sciences company’s stock worth $16,697,000 after buying an additional 7,040 shares in the last quarter. Bank of Nova Scotia boosted its position in shares of Illumina by 265.4% in the first quarter. Bank of Nova Scotia now owns 86,202 shares of the life sciences company’s stock worth $14,710,000 after buying an additional 62,612 shares in the last quarter. Aberdeen Asset Management PLC UK boosted its position in shares of Illumina by 8.4% in the first quarter. Aberdeen Asset Management PLC UK now owns 27,981 shares of the life sciences company’s stock worth $4,775,000 after buying an additional 2,158 shares in the last quarter. Finally, Eastern Bank purchased a new position in shares of Illumina during the first quarter worth $256,000. 93.91% of the stock is currently owned by institutional investors.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
What are top analysts saying about Illumina Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Illumina Inc. and related companies.